MAIA Biotechnology (MAIA) awards cash bonuses after recent capital raise

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. disclosed that its Board approved one-time cash bonuses for two senior executives following the company’s recent capital raise. On March 27, 2026, the Board granted a $312,610 bonus to Chief Executive Officer Vlad Vitoc and a $50,000 bonus to Head of Finance Jeffrey Himmelreich, paid on March 31, 2026.

The company also included customary cautionary language regarding forward-looking statements, outlining risks related to clinical studies, regulatory approvals, manufacturing, market acceptance, and intellectual property protection.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

CEO bonus: $312,610 Head of Finance bonus: $50,000 Bonus payment date: March 31, 2026 +1 more

4 metrics

CEO bonus $312,610 One-time bonus to CEO Vlad Vitoc approved March 27, 2026

Head of Finance bonus $50,000 One-time bonus to Head of Finance Jeffrey Himmelreich approved March 27, 2026

Bonus payment date March 31, 2026 Date bonuses were paid to both executives

Filing item Item 5.02 Departure/election/appointment/compensation of directors or officers

Key Terms

one-time bonus payments, emerging growth company, forward-looking statements, capital raise, +1 more

5 terms

one-time bonus payments financial

"approved one-time bonus payments of $312,610 to Vlad Vitoc"

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

forward-looking statements regulatory

"The Company cautions that all statements... are forward-looking statements."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

capital raise financial

"in consideration for their efforts in connection with the Company’s recent capital raise"

A capital raise is when a company brings in new money from investors or lenders by selling shares, debt, or other securities to fund operations, growth projects, or to pay liabilities. It matters to investors because it changes the company’s financial picture—adding cash that can enable expansion or avoid trouble, but also potentially reducing each existing owner’s share or increasing the company’s debt load, similar to putting fuel in a car to keep it running while changing who shares the ride or who pays for repairs.

preclinical and clinical studies technical

"the initiation, timing, cost, progress and results of our preclinical and clinical studies"

Understanding 8-K Material Events →

04/02/2026 - 04:15 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 27, 2026

MAIA Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-41455

83-1495913

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

444 West Lake Street, Suite 1700
Chicago, IL		60606
(Address of principal executive offices)		(Zip Code)

(312) 416-8592

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		MAIA		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 27, 2026, the Board of Directors of MAIA Biotechnology, Inc. (the “Company”) approved one-time bonus payments of $312,610 to Vlad Vitoc, the Company’s Chief Executive Officer and $50,000 to Jeffrey Himmelreich, the Company’s Head of Finance, in consideration for their efforts in connection with the Company’s recent capital raise. The bonus payments were made on March 31, 2026.

Forward-looking Statements

The Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form 8-K, or furnished herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement, including, but not limited to: (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates. Any forward-looking statement speaks only as of the date on which it was made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 2, 2026

	MAIA BIOTECHNOLOGY, INC.

	By:	/s/ Vlad Vitoc
	Name:	Vlad Vitoc
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What executive bonuses did MAIA (MAIA) approve in March 2026?

MAIA approved one-time cash bonuses for two executives. CEO Vlad Vitoc received $312,610 and Head of Finance Jeffrey Himmelreich received $50,000. The Board approved these bonuses on March 27, 2026, and the company paid them on March 31, 2026.

Why did MAIA (MAIA) award one-time bonuses to its executives?

MAIA’s Board awarded one-time bonuses in consideration of management’s efforts related to the company’s recent capital raise. The filing states these payments recognized the contributions of CEO Vlad Vitoc and Head of Finance Jeffrey Himmelreich to completing that financing activity.

When were the MAIA (MAIA) executive bonuses paid?

The one-time executive bonuses were paid on March 31, 2026. They followed a Board decision on March 27, 2026, to grant $312,610 to CEO Vlad Vitoc and $50,000 to Head of Finance Jeffrey Himmelreich for their work on a recent capital raise.

Which MAIA (MAIA) executives received special compensation?

CEO Vlad Vitoc and Head of Finance Jeffrey Himmelreich received special one-time bonus payments. Vitoc was granted $312,610 and Himmelreich $50,000, reflecting the Board’s recognition of their efforts tied to a recent capital raise completed by the company.

Does MAIA (MAIA) include forward-looking statements in this update?

Yes, MAIA includes a detailed forward-looking statements section. It highlights risks and uncertainties around clinical and preclinical studies, regulatory filings and approvals, product development and manufacturing, market acceptance, market size, and the company’s ability to secure and maintain intellectual property protection.

Filing Exhibits & Attachments

3 documents